Picture of Dancann Pharma A/S logo

DANCAN Dancann Pharma A/S Income Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Dancann Pharma A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.

R2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSPRESS
Standards:
DAS
DAS
DAS
DAS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue000.8745.716.07
Cost of Revenue
Gross Profit1.693.853.84
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses0.6275.8715.422.120.2
Operating Profit-0.627-5.87-14.5-16.4-14.1
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes-0.638-5.99-15.2-18.3-15.3
Provision for Income Taxes
Net Income After Taxes-0.5-4.25-11.8-16.1-12.3
Net Income Before Extraordinary Items
Net Income-0.5-4.25-11.8-16.1-12.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-0.5-4.25-11.8-16.1-12.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.021-0.18-0.378-0.227-0.087
Dividends per Share